Inflammatory Bowel Disease

JUNE 19, 2024

The Regueiro Report

Subcutaneous Infliximab or Vedolizumab For Maintenance Therapy in IBD; Fast-Acting Upadacitinib in Crohn’s

image
Professor of Medicine
Chief of the Digestive
Disease Institute
Cleveland Clinic, Cleveland

By Miguel Regueiro, MD, with Marcus A. Banks

In this month’s The Regueiro Report, I highlight two studies on medications to treat inflammatory bowel disease.

The first study in this month’s report, a meta-analysis, discusses switching to subcutaneous infliximab or vedolizumab (Entyvio, Takeda) during the maintenance phase of treatment for ulcerative colitis or Crohn’s